The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.
|Articles|February 5, 2004
NIDDK invites applications on research into epidemiology of interstitial cystitis
The National Institute of Diabetes and Digestive and Kidney Diseases has announced a request for applications (RFA) for a study entitled, "Interstitial Cystitis/Painful Bladder Syndrome: Epidemiology" (RFA-DK-04-009).
Advertisement
Advertisement
Related to this article
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Adding perioperative pembrolizumab to chemotherapy does not improve EFS in MIBC
2
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
3
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5